BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29309612)

  • 21. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
    Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
    Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
    Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
    Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis.
    Brandl L; Zhang Y; Kirstein N; Sendelhofert A; Boos SL; Jung P; Greten F; Rad R; Menssen A
    Neoplasia; 2019 Oct; 21(10):974-988. PubMed ID: 31442917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
    Audrito V; Messana VG; Moiso E; Vitale N; Arruga F; Brandimarte L; Gaudino F; Pellegrino E; Vaisitti T; Riganti C; Piva R; Deaglio S
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33419372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.
    Li YY; Wu C; Chen SM; Shah SS; Wangpaichitr M; Feun LG; Kuo MT; Suarez M; Prince J; Savaraj N
    Oncotarget; 2016 Apr; 7(14):17665-80. PubMed ID: 26771234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
    Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
    Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
    Tarrant JM; Dhawan P; Singh J; Zabka TS; Clarke E; DosSantos G; Dragovich PS; Sampath D; Lin T; McCray B; La N; Nguyen T; Kauss A; Dambach D; Misner DL; Diaz D; Uppal H
    Toxicol Mech Methods; 2015 Mar; 25(3):201-11. PubMed ID: 25894564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.
    Sharma R; Fedorenko I; Spence PT; Sondak VK; Smalley KS; Koomen JM
    J Proteome Res; 2016 Dec; 15(12):4476-4489. PubMed ID: 27934295
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
    Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
    [No Abstract]   [Full Text] [Related]  

  • 30. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
    Dietrich P; Kuphal S; Spruss T; Hellerbrand C; Bosserhoff AK
    Oncogene; 2018 Feb; 37(7):897-911. PubMed ID: 29059159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation.
    Li YY; Wu C; Shah SS; Chen SM; Wangpaichitr M; Kuo MT; Feun LG; Han X; Suarez M; Prince J; Savaraj N
    Mol Oncol; 2017 Dec; 11(12):1806-1825. PubMed ID: 29094484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors.
    Khamari R; Trinh A; Gabert PE; Corazao-Rozas P; Riveros-Cruz S; Balayssac S; Malet-Martino M; Dekiouk S; Joncquel Chevalier Curt M; Maboudou P; Garçon G; Ravasi L; Guerreschi P; Mortier L; Quesnel B; Marchetti P; Kluza J
    Cell Death Dis; 2018 Feb; 9(3):325. PubMed ID: 29487283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
    Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS
    Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.
    Wang T; Xiao M; Ge Y; Krepler C; Belser E; Lopez-Coral A; Xu X; Zhang G; Azuma R; Liu Q; Liu R; Li L; Amaravadi RK; Xu W; Karakousis G; Gangadhar TC; Schuchter LM; Lieu M; Khare S; Halloran MB; Herlyn M; Kaufman RE
    Clin Cancer Res; 2015 Apr; 21(7):1652-64. PubMed ID: 25617424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
    Koetz-Ploch L; Hanniford D; Dolgalev I; Sokolova E; Zhong J; Díaz-Martínez M; Bernstein E; Darvishian F; Flaherty KT; Chapman PB; Tawbi H; Hernando E
    Pigment Cell Melanoma Res; 2017 May; 30(3):328-338. PubMed ID: 28140520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF
    Aldaghi SA; Jalal R
    Chem Res Toxicol; 2019 Apr; 32(4):645-658. PubMed ID: 30829029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.